China
Africa
Explore chapters and articles related to this topic
Psychiatric disorders
Published in Anne Lee, Sally Inch, David Finnigan, Therapeutics in Pregnancy and Lactation, 2019
The use of depot antipsychotic preparations in pregnancy is not encouraged. There are no published data on the effects of zuclopenthixol, flupenthixol, pipothiazine and fluphenazine depot preparations in pregnancy. These agents cannot, if necessary, be withdrawn rapidly and the dose cannot be reduced towards delivery to limit neonatal withdrawal symptoms. Depot preparations should only be used where compliance is a problem.
Questions and Answers
Published in David Browne, Brenda Wright, Guy Molyneux, Mohamed Ahmed, Ijaz Hussain, Bangaru Raju, Michael Reilly, MRCPsych Paper I One-Best-Item MCQs, 2017
David Browne, Brenda Wright, Guy Molyneux, Mohamed Ahmed, Ijaz Hussain, Bangaru Raju, Michael Reilly
Answer: A. Flupenthixol decanoate is claimed to be more effective in depressed patients. Zuclopenthixol decanoate is believed to be more effective in aggressive patients, pipothiazine palmitate when EPSEs are problematic, and haloperidol decanoate in the prophylaxis of manic illness. Fluphenazine decanoate is said to be associated with depressed mood. [V. p. 42]
Psychopharmacology and mental health
Published in Chambers Mary, Psychiatric and mental health nursing, 2017
First generation antipsychotics are: phenothiazines (e.g. chlorpromazine, pipotiazine, fluphenazine), butyrophenones (e.g. haloperidol,) thioxanthenes (e.g. flupentixol, zuclopenthixol) and benzamides (e.g. sulpiride).
Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?
Published in Expert Opinion on Pharmacotherapy, 2021
Justin Faden, Natasha Kiryankova-Dalseth, Ruby Barghini, Leslie Citrome
In an observational, naturalistic, retrospective one-year mirror-image study, 17 patients with treatment resistant schizophrenia or schizoaffective disorder were evaluated [64]. Treatment resistance was defined by failed sequential trials of at least two different antipsychotics at adequate dosages, with at least one being a non-clozapine SGA. Patients were hospitalized between January 2010 and June 2015 and treated with combined clozapine and a LAI (haloperidol [n = 9], risperidone [n = 7], pipotiazine [n = 1]). They were evaluated for hospitalizations during one year before initiating the combined treatment and one year during regular treatment with the combination. Number and length of hospitalizations significantly decreased after introducing the combination (2.1 vs 0.8 [p = 0.004] and 155.4 days vs 26.6 days [p < 0.001] respectively), and no major adverse events occurred in terms of increased weight, agranulocytosis, hyperglycemia and/or dyslipidemia.
Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database
Published in Expert Opinion on Drug Safety, 2021
Samuel Bulteau, Marine Le Pierres, Pascal Artarit, Bastien Forestier, Emmanuelle Michaud, Anicet Chaslerie, Olivier Bonnot, Caroline Victorri-Vigneau
We include all new users (without any dispensing in the previous 6 months) of antipsychotic drugs, whatever the administration route, between 1 July 2013 and 31 December 2017, living in one area of France (Pays de la Loire, 3 787 411 inhabitants). The prevalence of AP exposure and demographic characteristics of the sample were compared to those of another nearby French area with the same population size (Brittany, 3.336 million inhabitants). Drugs were categorized using the Anatomical Therapeutic Chemical (ATC) classification system. The N05A and the N07XX06 groups included all APs with labels in France during the study period: chlorpromazine, levomepromazine, cyamemazine, periciazine, pipamperone, pimozide, fluphenazine, pipotiazine, haloperidol, flupentixol, zuclopenthixol, loxapine, clozapine, olanzapine, quetiapine, sulpiride, amisulpride, risperidone, aripiprazole, paliperidone, tiapride which belong to the N05A group and is used for agitation and neurologic conditions, tetrabenazine which belong to the N07XX06 group and used for hyperkinetic movement disorders, ziprasidone that reached approval in France in 2018 in treatment-resistant schizophrenia under nominative temporary authorization, and asenapine that received approval in 2011 in France for manic episode in bipolar disorder but is not available on the market anymore.
Capgras and Fregoli syndromes: delusion and misidentification
Published in International Review of Psychiatry, 2020
Antonio Ventriglio, Dinesh Bhugra, Domenico De Berardis, Julio Torales, João Mauricio Castaldelli-Maia, Andrea Fiorillo
Although there aren’t specific recommendations for the treatment of DMSs, we found some suggestions in the last decades literature. Bell et al. (2017) reviewed 84 clinical cases of DMSs over 25,000 medical records, and found that antipsychotic drugs have been largely used (66 patients/84), in particular: olanzapine (40), risperidone (37), aripiprazole (24), quetiapine (15), haloperidol (13), zuclopenthixol (9), clozapine (5), fluphenazine (4), pipotiazine (4), trifluoperazine (4), chlorpromazine (3) and sulpiride (2). The efficacy of olanzapine has been tested and confirmed also in a case report by Torales et al (2014).